Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Rhabdoid Tumor 3Pinealoma 3Neuroectodermal Tumors, Primitive 3Neoplasms, Germ Cell and Embryonal 3Medulloblastoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Glioma 3Ependymoma 3Choroid Plexus Carcinoma 3Central Nervous System Neoplasms 3Brain Neoplasms 3Lymphoma, Follicular 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Diffuse Intrinsic Pontine Glioma 1Dendritic Cell Sarcoma, Interdigitating 1CD7-Positive Hematological Malignancies 1Burkitt Lymphoma 1

Interventions

venetoclax 69Cyclophosphamide 53ibrutinib 44obinutuzumab 43acalabrutinib 42Rituximab 40fludarabine 37fludarabine phosphate 30Specimen Handling 29pirtobrutinib 25Biopsy 24zanubrutinib 23Whole-Body Irradiation 16Bendamustine Hydrochloride 15Magnetic Resonance Spectroscopy 14Mycophenolic Acid 13Lenalidomide 11Peripheral Blood Stem Cell Transplantation 9Sirolimus 8idelalisib 7Tacrolimus 7CT-P10 7ARQ531 7tafasitamab 6Prednisone 6Busulfan 6pembrolizumab 5Stem Cell Transplantation 5Melphalan 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Automobiles × 1 year × Clear all
NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 1 Recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡